UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
|
Item 5.08 |
Shareholder Director Nominations |
On February 27, 2023, the board of directors (the “Board”) of Gelesis Holdings, Inc. (the “Company”) established May 1, 2023, as the date for the Company’s 2023 Annual Meeting of Stockholders (the “Annual Meeting”). Due to the fact that the Company did not hold its annual meeting of stockholders in 2022 after its special meeting held in January 2022 in connection with its business combination, the Company is providing the due date for submission of any qualified stockholder proposal or qualified stockholder nominations. One or more of the proposals that the Company intends to present to its stockholders at the Annual Meeting will require the Company to file a preliminary proxy statement with the Securities and Exchange Commission (the “SEC”) prior to filing and mailing a definitive proxy statement relating thereto. Accordingly, the date of the Annual Meeting is subject to change, including as a result of any delays in the Company’s anticipated schedule for the Annual Meeting and SEC filings related thereto resulting from such SEC review process.
In accordance with Rule 14a-5(f) and Rule 14a-8(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Company’s amended and restated bylaws (the “Bylaws”), the deadline for receipt of stockholder proposals or nominations for inclusion in the Company’s proxy statement for the Annual Meeting pursuant to Rule 14a-8 will be no later than 5:00 p.m., Eastern Time, March 13, 2023, or the tenth (10th) day following this public announcement of the meeting date. Stockholder proposals must comply with all of the applicable requirements set forth in the rules and regulations of the SEC, including Rule 14a-8 under the Exchange Act and the Bylaws. Stockholder proposals and director nominations should be addressed to our Secretary, c/o Gelesis Holdings, Inc. 501 Boylston Street, Suite 6102, Boston, Massachusetts 02116.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
Gelesis Holdings, Inc. |
|
|
|
|
Date: |
March 3, 2023 |
By: |
/s/ Elliot Maltz |
|
|
|
Elliot Maltz Chief Financial Officer (Principal Financial Officer and Accounting Officer) |